


Appl. No.: 10/672,613
 Amendment dated January 5, 2006
 Reply to Office Action of October 5, 2005

Amendments to the Claims:

1. (Previously presented) A compound of the formula I



in which

R^1 is selected from:

- a) CONR^5R^6 , in which R^5 and R^6 independently of one another are H or $\text{C}_1\text{-C}_6\text{-alkyl}$;
- b) $\text{A-CONR}^5\text{R}^6$, in which A is $\text{C}_1\text{-C}_6\text{-alkylene}$ which is optionally substituted by $\text{C}_1\text{-C}_3\text{-alkyl-CO}$, and R^5 and R^6 independently of one another are H, $\text{C}_1\text{-C}_6\text{-alkyl}$ or phenyl which is optionally substituted by one or 2 halogen atoms with the proviso that R^5 and R^6 are not both H;
- c) $\text{C}_1\text{-C}_6\text{-alkylene-R}^7$, where R^7 is NR^5R^6 , and R^5 and R^6 independently of one another are H or $\text{C}_1\text{-C}_6\text{-alkyl}$;
- d) $\text{C}_1\text{-C}_6\text{-alkylene-CO-R}^9$, where R^9 is phenyl which is substituted by halogen, or $\text{C}_2\text{-C}_6\text{-alkylene-CO-R}^9$, where R^9 is phenyl which is optionally substituted by halogen;
- e) $\text{C}_1\text{-C}_6\text{-alkylene-NR}^{10}\text{-CO-R}^{11}$, or
- f) $\text{C}_1\text{-C}_6\text{-alkylene-NR}^{10}\text{-SO}^2\text{-R}^{12}$,

R^{10} is H or $\text{C}_1\text{-C}_6\text{-alkyl}$,

Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

R^{11} is

- naphthyl, or
- $\text{CH}=\text{CH}$ -phenyl;

R^{12} is

- phenyl which optionally has 1, 2 or 3 substituents which independently of one another are selected from halogen, NO_2 , CF_3 , $\text{OC}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_6\text{-alkyl}$, NH_2 and $\text{NHCOC}_1\text{-C}_3\text{-alkyl}$,
- $\text{C}_1\text{-C}_6\text{-alkyl}$ which is optionally substituted by one or two phenyl groups, or
- naphthyl,

R^2 is H, $\text{C}_1\text{-C}_6\text{-alkyl}$ or $(\text{CH}_2)_0\text{COOH}$,

R^3 and R^4 , which can be identical or different, are H, OH, $\text{OC}_1\text{-C}_6\text{-alkyl}$, halogen or $\text{C}_1\text{-C}_6\text{-alkyl}$ which is substituted by 1, 2 or 3 halogen atoms, where at least one of the radicals R^3 and R^4 is OH or $\text{OC}_1\text{-C}_6\text{-alkyl}$,

n is 0, 1 or 2 and

o is 0, 1, 2, 3 or 4,

and the optical isomers and physiologically tolerable salts thereof.

2. (Previously presented) A compound as claimed in claim 1, where R^1 is selected from:

- a) CONR^5R^6 , in which R^5 and R^6 independently of one another are H or $\text{C}_1\text{-C}_6\text{-alkyl}$;
- b) $\text{A-CONR}^5\text{R}^6$, in which A is $\text{C}_1\text{-C}_6\text{-alkylene}$ which is optionally substituted by $\text{C}_1\text{-C}_3\text{-alkyl-CO}$, and R^5 and R^6 independently of one another are H, $\text{C}_1\text{-C}_6\text{-}$

3 of 17

RTA01/2195914v1

Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

alkyl or phenyl which is optionally substituted by one or 2 halogen atoms, with the proviso that R^5 and R^6 are not both H;

c) C_1-C_6 -alkylene-CO- R^9 , where R^9 is phenyl which is substituted by halogen, or C_2-C_6 -alkylene-CO- R^9 , where R^9 is phenyl which is optionally substituted by halogen;

d) C_1-C_6 -alkylene-NR¹⁰-CO- R^{11} ;

e) C_1-C_6 -alkylene-NR¹⁰-SO²- R^{12} ,

R^{11} is naphthyl, or CH=CH-phenyl,

and R^2 , R^3 , R^4 , R^{10} and R^{12} have the meaning as indicated in claim 1.

3. (Original) A compound as claimed in claim 1, where both radicals R^3 and R^4 are a C_1 - C_6 -alkoxy group.

4. (Cancelled)

5. (Original) A compound as claimed in claim 1, where R^1 is A-CONR⁵R⁶ and A, R^5 and R^6 have the meanings indicated in claim 1.

6. (Currently amended) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene-CO- R^9 , in which R^9 is phenyl which is optionally substituted by halogen.

7. (Previously presented) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene- R^7 , in which R^7 is NR⁵R⁶, and R^5 and R^6 have the meanings indicated in claim 1.

8 - 11. (Cancelled)

Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

12. (Previously presented) A compound as claimed in claim 27, where R^{12} is naphthyl or phenyl which has 1, 2 or 3 substituents, which independently of one another are selected from halogen, NO_2 , CF_3 , OC_1-C_6 -alkyl, C_1-C_6 -alkyl, NH_2 and $NHCOC_1-C_3$ -alkyl.

13. (Previously presented) A compound as claimed in claim 27, where R^{12} is C_1-C_6 -alkyl which is optionally substituted by one or two phenyl groups.

14. (Previously presented) A compound as claimed in claim 1, where R^1 is C_1-C_6 -alkylene- NR^{10} -CO- R^{11} , in which R^{10} is H or C_1-C_3 -alkyl and R^{11} is -CH=CH-phenyl.

15. (Original) A compound as claimed in claim 14, where R^1 is C_1 -, C_2 - or C_3 -alkylene- NR^{10} -CO- R^{11} , in which R^{10} and R^{11} have the meanings indicated in claim 14.

16 - 20. (Cancelled)

21. (Original) A method for treating a disease that is connected with an immune system disorder, comprising administering a pharmaceutical composition comprising at least one compound as claimed in claim 1.

22. (Original) A method for treating inflammation, comprising topically applying a pharmaceutical composition comprising at least one compound as claimed in claim 1.

23. (Original) A procedure for the treatment of diseases which are connected with a disorder of the immune system, where an amount of a compound as claimed in claim 1 having an immunomodulating or cyclooxygenase-inhibiting action is administered to a person who needs treatment of this type.

24. (Previously presented) A compound as claimed in claim 1, wherein R^1 is C_2-C_6 -alkylene-CO- R^2 , in which R^2 is phenyl optionally substituted by halogen.

Appl. No.: 10/672,613


Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

25. (Previously presented) A compound as claimed in claim 1, wherein A is C₂-C₆ alkylene which is optionally substituted by C₁-C₃-alkyl-CO.

26. (Previously presented) A compound as claimed in claim 1, wherein n is 1 or 2.

27. (Previously presented) A compound of the formula I



in which

R¹ is selected from:

- CONR⁵R⁶, in which R⁵ and R⁶ independently of one another are H or C₁-C₆-alkyl,
- C₁-C₆-alkylene-NR¹⁰-CO-R¹¹, in which R¹¹ is naphthyl, or
- C₁-C₆-alkylene-NR¹⁰-SO²-R¹²;

R¹⁰ is H or C₁-C₆-alkyl;

R¹² is

- phenyl which optionally has 1, 2 or 3 substituents which independently of one another are selected from halogen, NO₂, CF₃, OC₁-C₆-alkyl, C₁-C₆-alkyl, NH₂ and NHCO-C₁-C₃-alkyl,
- C₁-C₆-alkyl which is optionally substituted by one or two phenyl groups,
- or
- naphthyl;

R² is H, C₁-C₆-alkyl or (CH₂)₆COOH;

6 of 17

RTA01/2195914v1

Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005


R^3 and R^4 , which can be identical or different, are H, OH, OC_1-C_6 -alkyl, halogen or C_1-C_6 -alkyl which is substituted by 1, 2 or 3 halogen atoms, where at least one of the radicals R^3 and R^4 is OH or OC_1-C_6 -alkyl;

n is 0, 1 or 2; and

o is 0, 1, 2, 3 or 4;

and the optical isomers and physiologically tolerable salts thereof.

28. (Previously presented) A cosmetic composition comprising:
one or more cosmetically acceptable additives; and
at least one compound of the formula I



in which

R^1 is selected from:

- a) $CONR^5R^6$, in which R^5 and R^6 independently of one another are H or C_1-C_6 -alkyl;
- b) $A-CONR^5R^6$, in which A is C_1-C_6 -alkylene which is optionally substituted by C_1-C_3 -alkyl-CO, and R^5 and R^6 independently of one another are H, C_1-C_6 -alkyl or phenyl which is optionally substituted by one or 2 halogen atoms;
- c) C_1-C_6 -alkylene- R^7 , where R^7 is NR^5R^6 or is $COOR^8$, wherein R^5 and R^6 independently of one another are H or C_1-C_6 -alkyl and R^8 is H or C_1-C_6 -alkyl;
- d) C_1-C_6 -alkylene-CO- R^9 , where R^9 is phenyl which is optionally substituted by halogen;

Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

e) C_1-C_6 -alkylene- NR^{10} -CO- R^{11} ; or

f) C_1-C_6 -alkylene- NR^{10} -SO²- R^{12} ;

R^{10} is H or C_1-C_6 -alkyl;

R^{11} is

- phenyl which is optionally substituted by 1, 2 or 3 substituents, which independently of one another are selected from halogen, CN, NO₂, CF₃, OC_{1-C₆}-alkyl and C_1-C_6 -alkyl,

- naphthyl,

- C_1-C_6 -alkyl which is optionally substituted by 1 or 2 phenyl groups,

- C_2-C_6 -alkenyl,

- CH=CH-phenyl, or

- NR^5R^6 , where R^5 and R^6 independently of one another are H or C_1-C_6 -alkyl;

R^{12} is

- phenyl which optionally has 1, 2 or 3 substituents which independently of one another are selected from halogen, NO₂, CF₃, OC_{1-C₆}-alkyl, C_1-C_6 -alkyl, NH_2 and $NHCOC_1-C_3$ -alkyl,

- C_1-C_6 -alkyl which is optionally substituted by one or two phenyl groups, or

- naphthyl;

R^2 is H, C_1-C_6 -alkyl or $(CH_2)_6COOH$;

R^3 and R^4 , which can be identical or different, are H, OH, OC_{1-C₆}-alkyl, halogen or C_1-C_6 -alkyl which is substituted by 1, 2 or 3 halogen atoms, where at least one of the radicals R^3 and R^4 is OH or OC_{1-C₆}-alkyl;

n is 0, 1 or 2; and

o is 0, 1, 2, 3 or 4;

and the optical isomers and physiologically tolerable salts thereof.


Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

29. (Previously presented) A cosmetic composition as claimed in claim 28, wherein R^7 is NR^5R^6 , and R^5 and R^6 are as defined in claim 28.

30. (Previously presented) A cosmetic or pharmaceutical composition comprising at least one compound of the formula I



in which

R^1 is selected from:

- a) $CONR^5R^6$, in which R^5 and R^6 independently of one another are H or C_1 - C_6 -alkyl;
 - b) $A-CONR^5R^6$, in which A is C_1 - C_6 -alkylene which is optionally substituted by C_1 - C_3 -alkyl-CO, and R^5 and R^6 independently of one another are H, C_1 - C_6 -alkyl or phenyl which is optionally substituted by one or 2 halogen atoms;
 - c) C_1 - C_6 -alkylene- R^7 , where R^7 is NR^5R^6 , and R^5 and R^6 independently of one another are H or C_1 - C_6 -alkyl;
 - d) C_1 - C_6 -alkylene-CO- R^9 , where R^9 is phenyl which is optionally substituted by halogen;
 - e) C_1 - C_6 -alkylene- NR^{10} -CO- R^{11} ; or
 - f) C_1 - C_6 -alkylene- NR^{10} -SO $_2$ - R^{12} ;
- R^{10} is H or C_1 - C_6 -alkyl;
- R^{11} is
- naphthyl, or

Appl. No.: 10/672,613

Amendment dated January 5, 2006

Reply to Office Action of October 5, 2005

- CH=Cfl-phenyl;

R¹² is

- phenyl which optionally has 1, 2 or 3 substituents which independently of one another are selected from halogen, NO₂, CF₃, OC₁-C₆-alkyl, C₁-C₆-alkyl, NH₂ and NHCOC₁-C₃-alkyl,

- C₁-C₆-alkyl which is optionally substituted by one or two phenyl groups, or

- naphthyl;

R² is H, C₁-C₆-alkyl or (CH₂)₆COOH;

R³ and R⁴, which can be identical or different, are H, OH, OC₁-C₆-alkyl, halogen or C₁-C₆-alkyl which is substituted by 1, 2 or 3 halogen atoms, where at least one of the radicals R³ and R⁴ is OH or OC₁-C₆-alkyl;

n is 0, 1 or 2; and

o is 0, 1, 2, 3 or 4;

and the optical isomers and physiologically tolerable salts thereof.

31. (New) A method for treating a disease that is capable of treatment through inhibition of cyclooxygenase, comprising administering a pharmaceutical composition comprising at least one compound as claimed in claim 1.

32. (New) A method for treating a disease that is connected with an immune system disorder, comprising administering a pharmaceutical composition comprising at least one compound as claimed in claim 1, wherein said disease is selected from the group consisting of premature labor, colon carcinoma, Alzheimer's disease, rheumatoid arthritis, gout, septic shock, osteoporosis, neuropathic pain, alopecia, psoriasis, acute pancreatitis, rejection reactions in allogenic transplants, allergically caused pneumonia, arteriosclerosis, multiple sclerosis, cachexia, inflammatory bowel disease, adenomatous polypsis, inhibition of angiogenesis in connection with oncoses, contact eczema, and erythema.

Appl. No.: 10/672,613
Amendment dated January 5, 2006
Reply to Office Action of October 5, 2005

33. (New) A procedure for the treatment of diseases which are connected with a disorder of the immune system, where an amount of a compound as claimed in claim 1 having a cyclooxygenase-inhibiting action is administered to a person who needs treatment of this type.

34. (New) A procedure for the treatment of diseases which are connected with a disorder of the immune system, where an amount of a compound as claimed in claim 1 having an immunomodulating or cyclooxygenase-inhibiting action is administered to a person who needs treatment of this type, and wherein said disease is selected from the group consisting of premature labor, colon carcinoma, Alzheimer's disease, rheumatoid arthritis, gout, septic shock, osteoporosis, neuropathic pain, alopecia, psoriasis, acute pancreatitis, rejection reactions in allogenic transplants, allergically caused pneumonia, arteriosclerosis, multiple sclerosis, cachexia, inflammatory bowel disease, adenomatous polyposis, inhibition of angiogenesis in connection with oncoses, contact eczema, and erythema.